Aicher L, Meier G, Norcross A J, Jakubowski J, Varela M C, Cordier A, Steiner S
Preclinical Safety, Toxicology SMU-881, Novartis Pharma Ltd., Basel, Switzerland.
Biochem Pharmacol. 1997 Mar 7;53(5):723-31. doi: 10.1016/s0006-2952(96)00772-1.
The use of the immunosuppressant cyclosporine A (CsA) is limited by its adverse renal effects. Most recently, we reported that the drug markedly decreases the levels of the calcium-binding protein calbindin-D 28kDa in kidneys of male Wistar rats. In the present study, the potential relationship between drug-induced nephrotoxicity and the decrease in kidney calbindin-D 28kDa was investigated. Four groups of male Wistar rats were treated for 10 or 31 days with either the immunosuppressant CsA (50 mg/kg/day), FK-506 (5 mg/kg/day), rapamycin (5 mg/kg/day) or with the nonimmunosuppressive cyclosporine derivative 3'keto-[Bmt1]-[Val2]-CsA (SDZ PSC-833) (50 mg/kg/day), and the effects on calcium homeostasis, kidney histology and renal calbindin-D 28kDa were examined. Similar effects were found with CsA and FK-506; both drugs strongly reduced kidney calbindin-D 28kDa protein levels, increased urine calcium excretion, caused intratubular calcification, and induced basophilic tubules. In contrast, rapamycin and SDZ PSC-833 caused no decrease in renal calbindin-D 28kDa levels, no noticeable alterations in calcium metabolism, and no renal calcification. The results provide evidence for a link between decreased renal calbindin, increased calcium urine excretion, and intratubular kidney calcification. The present data show no correlation between the decrease in renal calbindin and the induction of basophilic tubules; however, it needs to be investigated if these apparently independent kidney effects may have a common origin upstream of calbindin expression.
免疫抑制剂环孢素A(CsA)的使用因其对肾脏的不良影响而受到限制。最近,我们报道该药物可显著降低雄性Wistar大鼠肾脏中钙结合蛋白钙结合蛋白-D 28kDa的水平。在本研究中,我们调查了药物诱导的肾毒性与肾脏钙结合蛋白-D 28kDa水平降低之间的潜在关系。将四组雄性Wistar大鼠分别用免疫抑制剂CsA(50 mg/kg/天)、FK-506(5 mg/kg/天)、雷帕霉素(5 mg/kg/天)或非免疫抑制性环孢素衍生物3'酮-[Bmt1]-[Val2]-CsA(SDZ PSC-833)(50 mg/kg/天)治疗10天或31天,并检测其对钙稳态、肾脏组织学和肾脏钙结合蛋白-D 28kDa的影响。CsA和FK-506产生了相似的效果;两种药物均强烈降低了肾脏钙结合蛋白-D 28kDa的蛋白水平,增加了尿钙排泄,导致肾小管内钙化,并诱导了嗜碱性肾小管。相比之下,雷帕霉素和SDZ PSC-833并未导致肾脏钙结合蛋白-D 28kDa水平降低,对钙代谢无明显改变,也未引起肾脏钙化。这些结果为肾脏钙结合蛋白降低、尿钙排泄增加和肾小管内肾脏钙化之间的联系提供了证据。目前的数据表明肾脏钙结合蛋白的降低与嗜碱性肾小管的诱导之间没有相关性;然而,这些明显独立的肾脏效应是否可能在钙结合蛋白表达的上游有共同的起源,仍有待研究。